RT Conference Proceedings
T1 Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials
A1 Raimondi, A.
A1 Morano, F.
A1 Trarbach, T.
A1 Karthaus, M.
A1 Lonardi, S.
A1 Fruehauf, S.
A1 Cremolini, C.
A1 Graeven, U.
A1 Bittoni, A.
A1 Mueller, L.
A1 Bianchi, A. Sartore
A1 Aranda, E.
A1 Boige, V.
A1 Stintzing, S.
A1 Di Bartolomeo, M.
A1 Koenig, A.
A1 Pietrantonio, F.
A1 Modest, D.
K1 Panitumumab
K1 Bevacizumab
K1 Proto-oncogene proteins B-raf
AB Background: In metastatic colorectal cancer (mCRC), after a first-line induction with doublet/triplet chemotherapy plus bevacizumab, fluoropyrimidine+bevacizumab is the recommended maintenance option. The combination of anti-EGFR agents and chemotherapy is a guideline-endorsed first-line option for RAS/BRAF wild-type (wt) mCRC patients, but the optimal maintenance schedule has not been defined, yet. The Valentino trial showed that, after 4-month FOLFOX+panitumumab induction, singleagent  panitumumab induced inferior progression-free survival (PFS) than FUFA+panitumumab, though slightly reducing toxicity. The Panama study demonstrated that, after 3-month FOLFOX+panitumumab induction, FUFA+panitumumab induced a significantly superior PFS than FUFA alone.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-06-01
LK http://hdl.handle.net/10668/21914
UL http://hdl.handle.net/10668/21914
LA en
NO Raimondi A, Morano F, Trarbach T, Karthaus M, Lonardi S, Fruehauf S, et al. SO-21 Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials. Annals Of Oncology [Internet]. 1 de junio de 2022;33:S366
DS RISalud
RD Apr 14, 2025